Table 1.

Clinical and genomic characteristics of the metaplastic PDX models

ID	Type of graft	Age at diagnosis	BRCA mutational status	T	N	M	Breast surgery	Node surgery	Histologic type	Lymphovascular invasion	SBR grade	Chemotherapy (CT)	Type of CT	RT	Local relapse	Distant relapse	MFS (months)	OS (months)
HBCx-66	Residual disease post NCA	38	BRCA1	2	0	0	Mastectomy	Lymphadenectomy	Fusiform	No	3	Primary	Sequential	Yes	0	0	69	69
HBCx-90	Residual disease post NCA	77	No mutation	4d	0	0	Mastectomy	No	Fusiform	Yes	2	Primary	Taxane-based	Yes	1	1	11.5	11.5
HBCx-130	Residual disease post NCA	73	No mutation	2	0	0	Mastectomy	Sentinel lymph node biopsy	Squamous	No	3	Primary	Sequential	Yes	1	1	19	22
HBCx-162	Residual disease post NCA	48	No mutation	2	0	0	Tumorectomy	Sentinel lymph node biopsy	Chondroid and fusiform	No	3	Primary	Sequential	Yes	0	0	14	14
HBCx-165	Primary breast cancer	89	No mutation	2	0	0	Tumorectomy	Sentinel lymph node biopsy	Squamous	No	3	Adjuvant	Capecitabine	Yes	0	1	12	14
HBCx-178	Residual disease post NCA	61	No mutation	2	0	0	Tumorectomy	Sentinel lymph node biopsy	Squamous	No	3	Primary	Sequential	Yes	0	0	9	9
HBCx-23	Primary breast cancer	41	No mutation	1	0	0	Tumorectomy	Lymphadenectomy	Chondroid and fusiform	Yes	3	Adjuvant	Anthracyclin-based	Yes	0	0	83	83
HBCx-60	Primary breast cancer	30	No mutation	3	1	0	Mastectomy	Lymphadenectomy	Fusiform	No	3	Adjuvant	Sequential	Yes	0	1	103	106
HBCx-70	Residual disease post NCA	51	No mutation	2	0	0	Mastectomy	Lymphadenectomy	Squamous and chondroid	No	3	Primary	Sequential	Yes	0	1	15	27

TNM tumor, node, metastasis classification, SBR Scarff Bloom and Richardson, CT chemotherapy, RT radiotherapy, MFS metastasis-free survival, OS overall survival